newsfilter
← Earnings
Earnings Releases·

Caris Life Sciences — Third Quarter 2026 Earnings Summary

Caris Life Sciences reported third-quarter 2026 total revenue of $275.4 million, representing a 27% increase year-over-year driven by 21% growth in clinical case volume to approximately 61,500 cases. The company achieved a gross margin of 66% and reported net income of $15.3 million, while raising its full-year 2026 revenue guidance to a range of $1.04 to $1.05 billion. Operating expenses increased by 42% to $163.0 million due to expanded headcount, research and development investments, and marketing expenditures. Additionally, the company launched new therapeutic monitoring services and surpassed 1.2 million total molecular profiles through the end of the third quarter.

Company
CARIS LIFE SCIENCES INC
Sector
Healthcare
Industry
Biotechnology